{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T19:54:07Z","timestamp":1793908447376,"version":"4.8.0"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,6,1]],"date-time":"2021-06-01T00:00:00Z","timestamp":1622505600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,3,25]],"date-time":"2021-03-25T00:00:00Z","timestamp":1616630400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100014382","name":"Ipsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100014382","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["esmoopen.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["ESMO Open"],"published-print":{"date-parts":[[2021,6]]},"DOI":"10.1016\/j.esmoop.2021.100119","type":"journal-article","created":{"date-parts":[[2021,4,23]],"date-time":"2021-04-23T15:12:00Z","timestamp":1619190720000},"page":"100119","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"title":["Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index &lt;55%: single-arm phase II study"],"prefix":"10.1016","volume":"6","author":[{"given":"H.","family":"Jeong","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Shin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.H.","family":"Jeong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.-p.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.-M.","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.-i.","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.-S.","family":"Ryu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.-Y.","family":"Ryoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Yoo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.esmoop.2021.100119_bib1","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \u201ccarcinoid\u201d: epidemiology of and prognostic factors for neuroendocrine tumors in 35\u2009825 cases in the United States","volume":"26","author":"Yao","year":"2008","journal-title":"J\u00a0Clin Oncol."},{"issue":"10","key":"10.1016\/j.esmoop.2021.100119_bib2","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1001\/jamaoncol.2017.0589","article-title":"Trends in the incidence, prevalence, and survival outcomes in patients with neuroendocrine tumors in the United States","volume":"3","author":"Dasari","year":"2017","journal-title":"JAMA Oncol."},{"issue":"12","key":"10.1016\/j.esmoop.2021.100119_bib3","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1016\/j.neo.2017.09.002","article-title":"Nothing but NET: a review of neuroendocrine tumors and carcinomas","volume":"19","author":"Oronsky","year":"2017","journal-title":"Neoplasia."},{"issue":"11","key":"10.1016\/j.esmoop.2021.100119_bib4","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1053\/hupa.2002.129204","article-title":"Classification of low-grade neuroendocrine tumors of midgut and unknown origin","volume":"33","author":"van Eeden","year":"2002","journal-title":"Hum Pathol."},{"key":"10.1016\/j.esmoop.2021.100119_bib5","series-title":"WHO classification of tumours of the digestive system","author":"Bosman","year":"2010"},{"issue":"2","key":"10.1016\/j.esmoop.2021.100119_bib6","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1097\/PAS.0b013e3182417d36","article-title":"Small cell and large cell neuroendocrine carcinomas of the pancreas are genetically similar and distinct from well-differentiated pancreatic neuroendocrine tumors","volume":"36","author":"Yachida","year":"2012","journal-title":"Am J Surg Pathol."},{"key":"10.1016\/j.esmoop.2021.100119_bib7","series-title":"WHO Classification of Tumours of Endocrine Organs","year":"2017"},{"issue":"6","key":"10.1016\/j.esmoop.2021.100119_bib8","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1097\/MPA.0b013e3181ebb56f","article-title":"The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas","volume":"39","author":"Strosberg","year":"2010","journal-title":"Pancreas."},{"issue":"2","key":"10.1016\/j.esmoop.2021.100119_bib9","doi-asserted-by":"crossref","first-page":"291","DOI":"10.4143\/crt.2020.1233","article-title":"Systemic treatment of advanced gastroenteropancreatic neuroendocrine tumors in Korea: literature review and expert opinion","volume":"53","author":"Yoo","year":"2021","journal-title":"Cancer Res Treat."},{"issue":"7","key":"10.1016\/j.esmoop.2021.100119_bib10","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.annonc.2020.03.304","article-title":"Gastroenteropancreatic neuroendocrine neoplasms: ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Pavel","year":"2020","journal-title":"Ann Oncol."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100119_bib11","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye","year":"2013","journal-title":"Ann Oncol."},{"issue":"2","key":"10.1016\/j.esmoop.2021.100119_bib12","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/cncr.25425","article-title":"First-line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas","volume":"117","author":"Strosberg","year":"2011","journal-title":"Cancer."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100119_bib13","doi-asserted-by":"crossref","first-page":"206","DOI":"10.3390\/cancers12010206","article-title":"Outcomes of capecitabine and temozolomide (CAPTEM) in advanced neuroendocrine neoplasms (NENs)","volume":"12","author":"Thomas","year":"2020","journal-title":"Cancers (Basel)."},{"key":"10.1016\/j.esmoop.2021.100119_bib14","first-page":"9032753","article-title":"CAPTEM in metastatic well-differentiated intermediate to high grade neuroendocrine tumors: a single centre experience","volume":"2019","author":"Sahu","year":"2019","journal-title":"J\u00a0Oncol."},{"issue":"3","key":"10.1016\/j.esmoop.2021.100119_bib15","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00280-012-2055-z","article-title":"Capecitabine and temozolomide (CAPTEM) for metastatic, well-differentiated neuroendocrine cancers: the pancreas center at Columbia University experience","volume":"71","author":"Fine","year":"2013","journal-title":"Cancer Chemother Pharmacol."},{"issue":"1-2","key":"10.1016\/j.esmoop.2021.100119_bib16","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1159\/000500862","article-title":"Temozolomide alone or combined with capecitabine for the treatment of advanced pancreatic neuroendocrine tumor","volume":"110","author":"de Mestier","year":"2020","journal-title":"Neuroendocrinology."},{"issue":"2","key":"10.1016\/j.esmoop.2021.100119_bib17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1111\/his.13975","article-title":"The 2019 WHO classification of tumours of the digestive system","volume":"76","author":"Nagtegaal","year":"2020","journal-title":"Histopathology."},{"issue":"8","key":"10.1016\/j.esmoop.2021.100119_bib18","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1530\/ERC-16-0117","article-title":"MGMT expression predicts response to temozolomide in pancreatic neuroendocrine tumors","volume":"23","author":"Cros","year":"2016","journal-title":"Endocr Relat Cancer."},{"issue":"1","key":"10.1016\/j.esmoop.2021.100119_bib19","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1186\/s13550-020-00651-z","article-title":"Tumour-to-liver ratio determined by [(68)Ga]Ga-DOTA-TOC PET\/CT as a prognostic factor of lanreotide efficacy for patients with well-differentiated gastroenteropancreatic-neuroendocrine tumours","volume":"10","author":"Kim","year":"2020","journal-title":"EJNMMI Res."},{"issue":"suppl 2","key":"10.1016\/j.esmoop.2021.100119_bib20","first-page":"S219","article-title":"Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide","volume":"31","author":"Krenning","year":"1999","journal-title":"Ital J Gastroenterol Hepatol."},{"issue":"6","key":"10.1016\/j.esmoop.2021.100119_bib21","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1002\/sim.721","article-title":"Sample size tables for exact single-stage phase II designs","volume":"20","author":"A'Hern","year":"2001","journal-title":"Stat Med."},{"issue":"4","key":"10.1016\/j.esmoop.2021.100119_bib22","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1530\/ERC-15-0119","article-title":"Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms","volume":"22","author":"Heetfeld","year":"2015","journal-title":"Endocr Relat Cancer."},{"issue":"4","key":"10.1016\/j.esmoop.2021.100119_bib23","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1159\/000500135","article-title":"Activity and safety of standard and prolonged capecitabine\/temozolomide administration in patients with advanced neuroendocrine neoplasms","volume":"109","author":"Chatzellis","year":"2019","journal-title":"Neuroendocrinology."},{"issue":"suppl 3","key":"10.1016\/j.esmoop.2021.100119_bib24","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1200\/jco.2014.32.3_suppl.179","article-title":"Prospective phase II study of capecitabine and temozolomide (CAPTEM) for progressive, moderately, and well-differentiated metastatic neuroendocrine tumors","volume":"32","author":"Fine","year":"2014","journal-title":"J\u00a0Clin Oncol."},{"issue":"suppl 15","key":"10.1016\/j.esmoop.2021.100119_bib25","doi-asserted-by":"crossref","first-page":"4004","DOI":"10.1200\/JCO.2018.36.15_suppl.4004","article-title":"A\u00a0randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: a trial of the ECOG-ACRIN Cancer Research Group (E2211)","volume":"36","author":"Kunz","year":"2018","journal-title":"J\u00a0Clin Oncol."},{"issue":"10","key":"10.1016\/j.esmoop.2021.100119_bib26","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1056\/NEJMoa043331","article-title":"MGMT gene silencing and benefit from temozolomide in glioblastoma","volume":"352","author":"Hegi","year":"2005","journal-title":"N\u00a0Engl J Med."},{"issue":"3","key":"10.1016\/j.esmoop.2021.100119_bib27","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1038\/bjc.2014.660","article-title":"O6-Methylguanine-DNA methyltransferase status in neuroendocrine tumours: prognostic relevance and association with response to alkylating agents","volume":"112","author":"Walter","year":"2015","journal-title":"Br J Cancer."},{"issue":"9","key":"10.1016\/j.esmoop.2021.100119_bib28","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1530\/ERC-16-0147","article-title":"Analysis of potential response predictors to capecitabine\/temozolomide in metastatic pancreatic\u00a0neuroendocrine tumors","volume":"23","author":"Cives","year":"2016","journal-title":"Endocr Relat Cancer."},{"issue":"5","key":"10.1016\/j.esmoop.2021.100119_bib29","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1097\/SLA.0b013e3181fd37e8","article-title":"The impact of 68Ga-DOTATOC positron emission tomography\/computed tomography on the multimodal management of patients with neuroendocrine tumors","volume":"252","author":"Frilling","year":"2010","journal-title":"Ann Surg."},{"issue":"3","key":"10.1016\/j.esmoop.2021.100119_bib30","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1158\/1078-0432.CCR-09-1759","article-title":"18F-fluorodeoxyglucose positron emission tomography predicts survival of patients with neuroendocrine tumors","volume":"16","author":"Binderup","year":"2010","journal-title":"Clin Cancer Res."},{"issue":"61","key":"10.1016\/j.esmoop.2021.100119_bib31","doi-asserted-by":"crossref","first-page":"104046","DOI":"10.18632\/oncotarget.22001","article-title":"Combination therapy with capecitabine and temozolomide in patients with low and high grade neuroendocrine tumors, with an exploratory analysis of O(6)-methylguanine DNA methyltransferase as a biomarker for response","volume":"8","author":"Owen","year":"2017","journal-title":"Oncotarget."}],"container-title":["ESMO Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000776?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2059702921000776?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T20:24:48Z","timestamp":1761855888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2059702921000776"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2021,6]]}},"alternative-id":["S2059702921000776"],"URL":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100119","relation":{},"ISSN":["2059-7029"],"issn-type":[{"value":"2059-7029","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Capecitabine plus temozolomide in patients with grade 3 unresectable or metastatic gastroenteropancreatic neuroendocrine neoplasms with Ki-67 index <55%: single-arm phase II study","name":"articletitle","label":"Article Title"},{"value":"ESMO Open","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.esmoop.2021.100119","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Author(s). Published by Elsevier Ltd on behalf of European Society for Medical Oncology.","name":"copyright","label":"Copyright"}],"article-number":"100119"}}